NewLimit

NewLimit is a private, pre-clinical stage biotech focused on epigenetic reprogramming to combat aging and age-related diseases. The company is building a technology platform that integrates advanced genomics and machine learning to identify and develop therapies that can reset cellular age, starting with programs targeting the aging liver, immune, and vascular systems. Backed by prominent venture capital firms and strategic investors like Eli Lilly, NewLimit operates with a mission-driven, iterative R&D model aimed at translating fundamental biology into transformative medicines.

Integrated platform combining single-cell genomics, machine learning, high-throughput functional assays, and epigenetic editing to discover and develop partial reprogramming therapies that reset cellular age.

The field of epigenetic reprogramming for longevity is emerging but increasingly competitive, with several well-funded startups (e.g., Altos Labs, Retro Biosciences) and growing interest from large pharma. Differentiation will depend on platform efficiency, depth of biological insight, and clinical translation.